Fluvastatin-induced rhabdomyolysis

Annals of Pharmacotherapy

Volumn 36, Issue 12, 2002, Pages 1870-1874

  Modi, Jitu R ^a   Cratty, Michael S ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Creatine kinase; Fluvastatin; Renal failure; Rhabdomyolysis

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE; FLUINDOSTATIN; LACTATE DEHYDROGENASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; THYROTROPIN;

ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CYTOMEGALOVIRUS; ECHOGRAPHY; ENZYME BLOOD LEVEL; EPSTEIN BARR VIRUS; HEMATURIA; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; INFECTION; KIDNEY CORTEX; KIDNEY EXAMINATION; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE COUNT; LOW BACK PAIN; MALAISE; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOLYSIS; UREMIA; URINE CULTURE;

EID: 0036894537     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C029     Document Type: Article

References (34)

1. Davidson MH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 1994;96(suppl 5A):41S-4S.
2. Banga JD, Jachott B, Pfister P, Mehra M. Long-term treatment of hypercholesterolemia with fluvastatin: A 52-week Multicenter Safety and Efficacy Study. Am J Med 1994;96(suppl 6A):87-94.
3. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: Implications for therapeutic selection. Am J Med 2001; 111:390-400.
4. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL): I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151:43-9.
5. Jokubaitis LA. Updated clinical safety experience with fluvastafin. Am J Cardiol 1994;73:18D-24D.
6. McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993;15:57-64.
7. Peters TK. Safety profile of fluvastatin. Br J Clin Pract Suppl 1996; 77A:20-3.
8. Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811-5.
9. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995;521:639-45.
10. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
11. Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Am J Cardiol 1994;73:3D-11D.
12. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999;33:1176-9.
13. Pierce LR, Wyosowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5.
14. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-8.
15. Beisenbach G, Janko O, Stuby U, Zazgornik J. Myoglobinuric renal failure due to long standing lovastatin therapy in a patient with pre-existing renal insufficiency. Nephrol Dial Transplant 1996;11:2059-60.
16. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
17. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992;26:190-2.
18. Takei A, Chiba S. Rhabdomyolysis associated with pravastatin treatment for major depression (letter). Psychiatry Clin Neurosci 1999;53:539.
19. Berland Y, Vacher CH, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use (letter). Nephron 1991;57:365-6.
20. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
22. Visweswaran P, Guntupalli J. Rhabdomyolysis. Crit Care Clin 1999;15: 415-28.
23. Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: Three case reports and review. Clin Infect Dis 1996;22:642-9.
24. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001;50:984-6.
25. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
26. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994;73:12D-7D.
27. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, et al. Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
28. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary, report on safety. Am J Cardiol 1994;73:25D-9D.
29. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357-64.
30. Schrama YC, Hene RJ, De Jonge N, Joles JA, Van Rijn HJM, Bar DR, et al. Efficacy and muscle safety of fluvastatin in cyclosporine treated cardiac and renal transplant recipients: An exercise provocation test. Transplantation 1998;66:1175-81.
31. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience. J Clin Pharm Ther 1999;24:397-408.
32. Sinzinger H, Schmidt P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A reductase inhibitor treatment (letter). Arteriosclerosis 1999;143:459-60.
33. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patient treated with HMG-Co-A reductase inhibitors (letter). JAMA 1990;264:2992.
34. Weismantel D. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents (letter). J Fam Pract 2001;50:927.